Amino Acid, Peptide, or Protein
Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension
Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials
Marea Therapeutics Secures $190M for Cardiometabolic Medicine Development
Marea Therapeutics, cardiometabolic medicine, clinical-stage program, genetics, ANGPTL4, monoclonal antibody, phase 2 trial, metabolic dysfunction, cardiovascular disease.
J&J’s Nipocalimab Shows Promise in Sjögren’s Disease with Significant Phase 2 Results
nipocalimab, Sjögren’s disease, Johnson & Johnson, Phase 2 study, autoimmune disease, FcRn inhibitor
FDA Approves Pembrolizumab and Durvalumab for Endometrial Cancer Treatment
FDA, Pembrolizumab, Durvalumab, Endometrial Cancer, Immunotherapy, Chemotherapy
AstraZeneca’s IMFINZI Plus Chemotherapy Approved in the US for Mismatch Repair Deficient Endometrial Cancer
IMFINZI, durvalumab, endometrial cancer, mismatch repair deficient, chemotherapy, AstraZeneca, FDA approval
Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients
Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns
Gilead’s Magrolimab Linked to Increased Risk of Death in Blood Cancer Patients
Gilead, Magrolimab, Blood Cancer, Increased Risk of Death, ENHANCE Study
Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial
Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses
GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59
GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.
Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance
Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance